Skip to main content

Management of advanced hypopharyngeal carcinoma: systematic review of survival following surgical and non-surgical treatments

  • A Habib (a1)

Advanced hypopharyngeal carcinoma has a dismal prognosis. The optimal treatment for these patients remains under debate. This systematic review aimed to compare survival following surgical and non-surgical treatments.


A systematic review was conducted of randomised studies, with a descriptive analysis of retrospective observational studies.


Two randomised trials and 11 observational studies were included in the review. A meta-analysis of randomised trials reported a hazard ratio of 0.89 for overall survival in favour of surgical treatment (p = 0.44). Neither treatment was favoured in terms of overall survival. Observational studies did not report a survival advantage with either treatment. The five-year larynx preservation rates for non-surgically treated patients were between 38 and 58 percent.


Chemoradiotherapy offers similar survivorship compared to surgery in advanced disease, while also making larynx preservation feasible. It can be used as a treatment in all patients as an alternative to surgery.

Corresponding author
Address for correspondence: Dr Ayaaz Habib, Department of Ear, Nose and Throat, Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK E-mail:
Hide All
1Hall, SF, Groome, PA, Irish, J, O'Sullivan, B. The natural history of patients with squamous cell carcinoma of the hypopharynx. Laryngoscope 2008;118:1362–71.
2Edge, SB, Byrd, DR, Compton, C, Fritz, AG, Greene, FL, Trotti, A 3rd, eds. AJCC Cancer Staging Manual, 7th edn. New York: Springer, 2010.
3Edge, SB, Compton, CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of the TNM. Ann Surg Oncol 2010;17:1471–4.
4Hoffman, HT, Karnell, LH, Shah, JP, Ariyan, S, Brown, GS, Fee, WE et al. Hypopharyngeal cancer patient care evaluation. Laryngoscope 1997;107:1005–17.
5Pingree, TF, Davis, RK, Reichman, O, Derrick, L. Treatment of hypopharyngeal carcinoma: a 10 year review of 1,362 cases. Laryngoscope 1987;97:901–4.
6Wahlberg, PC, Andersson, KE, Biorklund, AT, Moller, TR. Carcinoma of the hypopharynx: analysis of incidence and survival in Sweden over a 30-year period. Head Neck 1998;20:714–19.
7Frank, JL, Garb, JL, Kay, S, McClish, DK, Bethke, KP, Lind, DS et al. Postoperative radiotherapy improves survival in squamous cell carcinoma of the hypopharynx. Am J Surg 1994;168:476–80
8Takes, RP, Strojan, P, Silver, CE, Bradley, PJ, Haigentz, M Jr, Wolf, GT et al. Current trends in initial management of hypopharyngeal cancer: the declining use of open surgery. Head Neck 2012;34:270–81.
9Reis, I, Aguiar, A, Alzamora, C, Ferreira, C, Castro, V, Soares, A et al. Locally advanced hypopharyngeal squamous cell carcinoma: single-institution outcomes in a cohort of patients curatively treated either with or without larynx preservation. Radiol Bras 2016;49:21–5.
10Bova, R, Goh, R, Poulson, M, Coman, WB. Total pharyngolaryngectomy for squamous cell carcinoma of the hypopharynx: a review. Laryngoscope 2005;115:864–9.
11Lefebvre, JL, Chevalier, D, Luboinski, B, Kirkpatrick, A, Collete, L, Sahmoud, T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996;88:890–9.
12Department of Veterans Affairs Laryngeal Cancer Study Group, Wolf, GT, Fisher, SG, Hong, WK, Hillman, R, Spaulding, M. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991;324:1685–90.
13Adelstein, DJ, Li, Y, Adams, GL, Wagner, H Jr, Kish, JA, Ensley, JF et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92–8.
14Vokes, EE, Kies, MS, Haraf, DJ, Stenson, K, List, M, Humerickhouse, R et al. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol 2000;18:1652–61.
15Altundag, O, Gullu, I, Altundag, K, Yalcin, S, Ozyar, E, Cengiz, M et al. Induction chemotherapy with cisplatin and 5-fluorouracil followed by chemoradiotherapy or radiotherapy alone in the treatment of locoregionally advanced resectable cancers of the larynx and hypopharynx: results of single-center study of 45 patients. Head Neck 2005;27:1521.
16Shin, DM, Glisson, BS, Khuri, FR, Lippman, SM, Ginsberg, L, Diaz, E Jr et al. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer 2002;95:322–30.
17Robson, A. Evidence-based management of hypopharyngeal cancer. Clin Otolaryngol 2002;27:413–20.
18American Joint Committee on Cancer. Manual for Staging of Cancer, 3rd edn. Philadelphia: Lippincott, 1988.
19PubMed, US National Library of Medicine, National Institutes of Health. In: [5 January 2017].
20Embase (produced by Elsevier). In: [6 January 2017].
21Scopus. In: [6 January 2017]
22Cochrane Library. In: [6 January 2017]
23Ovid technologies (Wolters Kluwer). In: [7 January 2017]
25Moher, D, Liberati, A, Tetzlaff, J, Altman, DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
26Vandersteen, C, Benezery, K, Chamorey, E, Ettaiche, M, Dassonville, O, Poissonnet, G et al. Contemporary therapeutic management of locally advanced hypopharyngeal cancer: oncologic and functional outcomes - a report on 100 cases. Acta Otolaryngol 2015;135:193200.
27Chang, MF, Wang, H, Kang, C, Huang, S, Lin, C, Fang, K et al. Treatment results for hypopharyngeal cancer by different treatment strategies and its secondary primary--an experience in Taiwan. Radiat Oncol 2010;5:91.
28Equator Network. Enhancing the QUAlity and Transparency Of health Research. In: [20 January 2017]
29CONSORT 2010. In: [20 January 2017]
30STROBE Statement. Strengthening the reporting of observational studies in epidemiology. In: [20 January 2017]
31Review Manager (RevMan) [computer program]. Version 5.3. Copenhagen: Nordic Cochrane Centre, Cochrane Collaboration, 2014.
32Higgins, JP, Green, S, eds. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 [updated March 2011]. Cochrane Collaboration, 2011.
33Beauvillain, C, Mahe, M, Bourdin, S, Peuvrel, P, Bergerot, P, Rivière, A et al. Final results of a randomized trial comparing chemotherapy plus radiotherapy with chemotherapy plus surgery plus radiotherapy in locally advanced resectable hypopharyngeal carcinomas. Laryngoscope 1997;107:648–53.
34Zelefsky, MJ, Kraus, DH, Pfister, DG, Raben, A, Shah, JP, Strong, EW et al. Combined chemotherapy and radiotherapy versus surgery and postoperative radiotherapy for advanced hypopharyngeal cancer. Head Neck 1996;18:405–11.
35Kim, JW, Kim, MS, Kim, S, Kim, JH, Lee, CG, Kim, GE et al. Definitive chemoradiotherapy versus surgery followed by adjuvant radiotherapy in resectable stage III/IV hypopharyngeal cancer. Cancer Res Treat 2016;48:4553.
36Jang, JY, Kim, E, Cho, J, Jung, J, Oh, D, Ahn, YC et al. Comparison of oncological and functional outcomes between initial surgical versus non-surgical treatments for hypopharyngeal cancer. Ann Surg Oncol 2016;23:2054–61.
37Lee, M, Ho, H, Hsiao, S, Hwang, J, Lee, C, Hung, S. Treatment results and prognostic factors in locally advanced hypopharyngeal cancer. Acta Otolaryngol 2008;128:103–9.
38Hung, SK, Chen, H, Hsieh, C, Hsu, W, Chang, K, Liu, D et al. Treatment of advanced hypopharyngeal cancer - comparison of two modalities. Tzu Chi Med J 2006;18:1521.
39Kim, S, Wu, H, Heo, D, Kim, K, Sung, M, Park, C. Advanced hypopharyngeal carcinoma treatment results according to treatment modalities. Head Neck 2001;23:713–17.
40Huang, W, Jen, Y, Chen, C, Su, Y, Lin, C, Lin, Y et al. Intensity modulated radiotherapy with concurrent chemotherapy for larynx preservation of advanced resectable hypopharyngeal cancer. Radiat Oncol 2010;5:37.
41Harris, BN, Biron, VL, Donald, P, Farwell, G, Luu, Q, Bewley, A et al. Primary surgery vs chemoradiation treatment of advanced-stage hypopharyngeal squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg 2015;141:636–40.
42Karnofsky Performance Status Scale Definitions Rating (%) Criteria. In: [21 February 2018]
43American Society of Anesthesiologists. ASA Physical Status Classification System. In: [21 February 2018]
44Argiris, A. Induction chemotherapy for head and neck cancer: will history repeat itself? J Natl Compr Canc Netw 2005;3:393403.
45Brockstein, B, Haraf, DJ, Rademaker, AW, Kies, MS, Stenson, KM, Rosen, F et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol 2004;15:1179–86.
46Pignon, JP, Bourhis, J, Domenge, C, Designe, L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: 3 meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355:949–55.
47Hitt, R, Lopez-Pousa, A, Martinez-Trufero, J, Escrig, V, Carles, J, Rizo, A et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005;23:8636–45.
48Posner, MR, Hershock, DM, Blajman, CR, Mickiewicz, E, Winquist, E, Gorbounova, V et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705–15.
49Vermorken, JB, Remenar, E, Herpen, C, Gorlia, T, Mesia, R, Degardin, M et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357:1695–704.
50Forastiere, AA, Goepfert, H, Maor, M, Pajak, TF, Weber, R, Morrison, W et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091–8.
51Prades, JM, Lallemant, B, Garrel, R, Reyt, E, Righini, C, Schmitt, T et al. Randomized phase III trial comparing induction chemotherapy followed by radiotherapy to concomitant chemoradiotherapy for laryngeal preservation in T3M0 pyriform sinus carcinoma. Acta Otolaryngol 2010;130:150–5.
52Bernier, J, Vermorken, JB, Koch, WM. Adjuvant therapy in patients with resected poor-risk head and neck cancer. J Clin Oncol 2006;24:2629–35.
53Bernier, J, Domenge, C, Ozsahin, M, Matuszewska, K, Lefebvre, JL, Greiner, RH et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945–52.
54Cooper, JS, Pajak, TF, Forastiere, AA, Jacobs, J, Campbell, BH, Saxman, SB et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:1937–44.
55Ensley, J, Crissman, J, Kish, J, Jacobs, J, Weaver, A, Kinzie, J et al. The impact of conventional morphologic analysis on response rates and survival in patients with advanced head and neck cancers treated initially with cisplatin-containing combination chemotherapy. Cancer 1986;57:711–17.
56Rooney, M, Kish, J, Jacobs, J, Kinzie, J, Weaver, A, Crissman, J et al. Improved complete response rate and survival in advanced head and neck cancer after 3-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer 1985;55:1123–8.
57Schuller, DE, Wilson, HE, Smith, RE, Batley, F, James, AD. Preoperative reductive chemotherapy for locally advanced carcinoma of the oral cavity, oropharynx, and hypopharynx. Cancer 1983;51:1519.
58Cohen, EE, Karrison, TG, Kocherginsky, M. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol 2014;32:2735–43.
59Haddad, R, O'Neill, A, Rabinowits, G. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase III trial. Lancet Oncol 2013;14:257–64.
60De Pooter, CM, Scalliet, PG, Elst, HJ, Huybrechts, JJ, Gheuens, E, Oosterom, A et al. Resistance patterns between cis-diamminedichloroplatinum (II) and ionizing radiation. Cancer Res 1991;51:4523–7.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The Journal of Laryngology & Otology
  • ISSN: 0022-2151
  • EISSN: 1748-5460
  • URL: /core/journals/journal-of-laryngology-and-otology
Please enter your name
Please enter a valid email address
Who would you like to send this to? *



Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed